1. ARID1A is a coactivator of STAT5 that contributes to CD8 + T cell dysfunction and anti-PD-1 resistance in gastric cancer.
- Author
-
Ma F, Ren M, Li Z, Tang Y, Sun X, Wang Y, Cao N, Zhu X, Xu Y, Wang R, Shen Y, Zhao R, Li Z, Ashrafizadeh M, Sethi G, Wang F, and Zhao A
- Subjects
- Humans, Male, Female, Cell Line, Tumor, Animals, Programmed Cell Death 1 Receptor antagonists & inhibitors, Programmed Cell Death 1 Receptor genetics, Programmed Cell Death 1 Receptor metabolism, Programmed Cell Death 1 Receptor immunology, Middle Aged, Mutation, Stomach Neoplasms drug therapy, Stomach Neoplasms genetics, Stomach Neoplasms immunology, STAT5 Transcription Factor metabolism, STAT5 Transcription Factor genetics, CD8-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes drug effects, CD8-Positive T-Lymphocytes metabolism, DNA-Binding Proteins genetics, DNA-Binding Proteins metabolism, Drug Resistance, Neoplasm genetics, Transcription Factors genetics, Immune Checkpoint Inhibitors therapeutic use, Immune Checkpoint Inhibitors pharmacology, Tumor Microenvironment immunology
- Abstract
ARID1A deletion mutation contributes to improved treatment of several malignancies with immune checkpoint inhibitors (ICIs). However, its role in modulating of tumor immune microenvironment (TIME) of gastric cancer (GC) remains unclear. Here, we report an increase of CD8
+ T cells infiltration in GC patients with ARID1A-mutation (MUT), which enhances sensitivity to ICIs. Kaplan-Meier survival analysis showed that ARID1A-mutation patients with gastrointestinal malignancies benefit from immunotherapy. Transcriptome analysis implicated that ARID1A regulates STAT5 downstream targets to inhibit T-cell mediated toxicity. Integrated dual luciferase assay and ChIP-qPCR analyses indicated that ARID1A coordinated with STAT5 to facilitate the transcription of the immunosuppressive factors TGF-β1 and NOX4. ARID1A recruited canonical BAF complex (cBAF) subunits, including SMARCB1 and SMARCD1, to sustain DNA accessibility. Downregulation of ARID1A reduced chromatin remodeling into configurations which make GC more sensitive to ICIs. In addition, targeting STAT5 effectively improved anti-PD-1 efficiency in ARID1A-wild type (WT) GC patients. Taken together, ARID1A is a coactivator of STAT5, function as a chromatin organizer in GC ICIs resistance, and targeting STAT5 is an effective strategy to improve the efficiency of ICIs in GC., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF